30 Jul 2025
🏥FDA Terminates Arthritis Advisory Committee Notice
Arthritis Advisory Committee; Termination
Summary
The Food and Drug Administration (FDA or the Agency) is announcing the termination of the Agency's Arthritis Advisory Committee (Committee) by the Commissioner of Food and Drugs (Commissioner). The Commissioner has determined that it is not necessary to continue to maintain this Committee.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$ - Low
The termination of the Arthritis Advisory Committee does not directly impact compliance or regulatory requirements for businesses. It primarily affects the FDA's internal advisory structure and does not present new opportunities or obligations for business owners or executives in the pharmaceutical or healthcare industries.